Analyst firms · Leerink Partners · THC

Leerink Partners THC price target and rating history

Tenet Healthcare Corporation (THC) · Health Care

Leerink Partners rates Tenet Healthcare Corporation (THC) Outperform with a $100 price target, as of its latest action on Feb 9, 2022. It has published 4 rating actions on THC since September 2021, including 1 upgrade and 0 downgrades.

Current rating
Outperform
Price target
$100
Median target, all firms
Too few
Actions on THC
4

Leerink Partners price target on THC

$100$89$7820222023202420252026
Leerink Partners price target on THC, each point a stated target, September 2021 to February 2022.

Every Leerink Partners rating on THC

Questions about Leerink Partners and THC

What is Leerink Partners's price target for THC?
Leerink Partners's latest stated price target for Tenet Healthcare Corporation (THC) is $100, from its action on Feb 9, 2022.
What is Leerink Partners's rating on THC?
Leerink Partners rates THC Outperform, a bullish rating, as of Feb 9, 2022.
When did Leerink Partners last change its view on THC?
On Feb 9, 2022, Leerink Partners upgrades to Outperform from Market Perform, price target $88 to $100.

More THC rating histories

All Leerink Partners ratingsTHC news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.